Promising
S1P receptor modulation (lymphocyte trafficking): repair myelin in relapsing MS
relapsing MS · S1P receptor modulation (lymphocyte trafficking)
A controlled phase 2 trial was positive. Phase 2 trials are small and often measure early markers, so this is a signal, not proof.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 88
Deciding trials (phase 2): 1 met, 0 did not.
Other linked trials: 0
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 0
These linked trials do not set the status.
- MOVINGMet main goal
Phase 3 · 2012 · Compared with interferon beta-1b
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-30Status changed from Confirmed to Promising
- 2026-10-28Status changed from No clear answer to Confirmed
- 2026-10-27First listed as No clear answer
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error